Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel

The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers. The Chicago-area pharma giant has signed ...